Navigation Links
Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Date:2/12/2009

SUNNYVALE, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a developmental stage biopharmaceutical company with four drug candidates in clinical testing and several late stage preclinical programs, announced today the appointment of a new management team and a new board member.

Robert W. Duggan, our Chairman of the Board, has been appointed CEO of the company after acting as interim CEO for the past five months. Mr. Duggan is considered one of the founders of robotic surgery. He served as Chairman of the Board of Directors of Computer Motion, Inc., a computerized surgical systems company, from 1990 to 2003 and Chief Executive Officer from 1997. Computer Motion was acquired by Intuitive Surgical, Inc. in 2003. Mr. Duggan currently serves as a director of Intuitive Surgical, Inc. Mr. Duggan has been a private venture investor for more than 30 years and has participated as a director of, investor in and advisor to numerous small and large businesses in the medical equipment, computer local and wide area network, PC hardware and software distribution, digital encryption, consumer retail goods and outdoor media communication industries. He received the Congressman's Medal of Merit and in 2000 he was named a Knight of the Legion of Honor by President Jacques Chirac. He is a member of the University of California at Santa Barbara Foundation Board of Trustees. Mr. Duggan has been a member of Pharmacyclics' Board of Directors since September 2007.

Glenn C. Rice, Ph.D has been appointed President and COO. Dr. Rice has over 25 years of oncology drug development experience in the biopharmaceutical industry including research, preclinical and clinical trials as well as extensive experience in licensing, partnerships and M&A. He was the CEO and Founder of Bridge Laboratories (a la
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Secures $5.0 Million in Debt Financing
2. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
4. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
5. Pharmacyclics Announces It Received Nasdaq Notification
6. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
7. Savient Announces Appointment of David Gionco as Chief Financial Officer
8. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
9. SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
10. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
11. Cord Blood Announces $1 Million Reduction in Long Term Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... June 30, 2014. Highlights , ... million in the same period last year. , Second ... million in the same period last year (see table at ... sales guidance increased, excluding the impact of foreign currency, to ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , July 31, 2014 Nearly 20,000 medical ... Annual Meeting & Clinical Lab Expo in ... featured never-before-seen breakthroughs in diagnostic research and technology that ... need. As of Wednesday, July 30, more ... Annual Meeting & Clinical Lab Expo, with more than ...
(Date:7/31/2014)... to see through organs and even the entire body ... fine-grained cellular structures has been a long-time dream of ... July 31st in the journal Cell has ... for making opaque organs, bodies, and human tissue biopsies ... The protocols could pave the way for a better ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3See-through organs and bodies will accelerate biomedical discoveries 2
... , Multiporator , , , , , , , ... Protocol No. 4308 915.032 03/2000 , , , ... , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.508 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.538 04/2002 , , , ... , , Microorganism , ... Cell type , Bacteria, gram positive, , ...
Cached Biology Technology:BW 5147 2Brucella abortus 2Bifidobacterium animalis 2
(Date:7/31/2014)... the National Science Foundation (NSF), counters a widely-held ... warming, indicating instead that certain Arctic lakes store ... atmosphere. , The study, published this week ... thermokarst lakes, which occur as permafrost thaws and ... water, converting what was previously frozen land into ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... 100 percent of animal models against the highly infectious ... an intestinal disease that kills approximately 30,000 Americans annually. ... Infection and Immunity . , In the study, ... the purified toxins produced by C. difficile , ... laboratory model that mimics the human disease, after only ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... release is available in German . , ... - a North African bird species with a very ... from attractive males of the same species positively affects ... highly displaying male birds in the experiment were more ...
... Institute of Standards and Technology (NIST) scientists have moved a ... blood test that can scan for thousands of disease markers ... has learned how to decode the electrical signals generated by ... artificial cell membrane. Nanopores are not new themselves; for ...
... of atherosclerosis has allowed researchers to identify a host of ... the process, before a plaque appears in the affected blood ... Blood, the journal of the American Society of Hematology. ... disturbances in the patterns of blood flow in an artery ...
Cached Biology News:Pleasing to the eye 2Pleasing to the eye 3NIST team advances in translating language of nanopores 2To predict atherosclerosis, follow the disturbed blood flow 2
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Biology Products: